Natriuretic Peptide Testing for Cardiac Amyloidosis: Clinical Effectiveness, Cost-Effectiveness and Guidelines

Details

Files

Project Line:

Reference List

Project Sub Line:

Summary of Abstracts

Project Number:

RB1365-000

Question

What is the clinical utility of natriuretic peptide testing for diagnosis and prognosis of light chain cardiac amyloidosis?
What is the cost-effectiveness of natriuretic peptide testing for diagnosis and prognosis of light chain cardiac amyloidosis?
What are the evidence-based guidelines for natriuretic peptide testing for monitoring of light chain cardiac amyloidosis?

Key Message

Three non-randomized studies were identified regarding the clinical utility of natriuretic peptide testing for diagnosis and prognosis of light chain cardiac amyloidosis. In addition, two evidence-based guidelines were identified regarding natriuretic peptide testing for monitoring of light chain cardiac amyloidosis. No economic evaluations were identified regarding the cost-effectiveness of natriuretic peptide testing for diagnosis and prognosis of light chain cardiac amyloidosis

Files

Natriuretic Peptide Testing for Cardiac Amyloidosis: Clinical Effectiveness, Cost-Effectiveness and Guidelines Rapid Response August 14, 2019 View PDF

Last Updated : August 14, 2019